A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer

Trial Details

NCT ID
NCT06512051
Phase
PHASE1 / PHASE2
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SHR-A2102 for Injection
  • Adebrelimab Injection
  • Cisplatin injection
  • Carboplatin injection
  • Bevacizumab Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural …
  • The age of signing the informed consent is 18 -70 years, regardless of gender.
  • Provide archived or fresh tumor tissue for vendor test.
  • At least one measurable lesion according to RECIST v1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →